Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

Lancet. 2020 May 2;395(10234):1407-1409. doi: 10.1016/S0140-6736(20)30858-8. Epub 2020 Apr 9.
No abstract available

MeSH terms

  • Antibodies / therapeutic use
  • Betacoronavirus
  • COVID-19
  • Clinical Trials as Topic*
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / immunology
  • Cytokines / metabolism
  • Humans
  • Inflammation* / complications
  • Inflammation* / drug therapy
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / immunology
  • SARS-CoV-2
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies
  • Cytokines
  • Tumor Necrosis Factor-alpha

Supplementary concepts

  • COVID-19 drug treatment